Trial intelligence / Profile preview

AZALEA study of azacitidine + lenalidomide in relapsed or refractory non-M3 acute myeloid leukemia

2015-001767-40Phase 2Terminated

Sponsor: Ospedali Riuniti Marche Nord
Start: Sep 2021
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of azacitidine and lenalidomide in acute myeloid leukemia (AML), sponsored by Ospedali Riuniti Marche Nord. Primary endpoint: Complete remission rate. Started Sep 2021; status: terminated.

Drugs

azacitidinelenalidomide

Conditions

acute myeloid leukemia (AML)

Beyond the preview

Go deeper on 2015-001767-40.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2015-001767-40.